Prognostic Significance of the Percentage of Blasts with CD34/CD38/CD123Phenotype in Acute Myeloid Leukemias.

Li-li Xiang; Guo-qiang Qiu; Xiao-bao Xie; Jian-nong Cen; Shao-yan HU; Wei-ying GU

Return

Prognostic Significance of the Percentage of Blasts with CD34/CD38/CD123Phenotype in Acute Myeloid Leukemias.

Author: Li-Li XIANG ¹ ; Guo-Qiang QIU ² ; Xiao-Bao XIE ³ ; Jian-Nong CEN ⁴ ; Shao-Yan HU ⁵ ; Wei-Ying GU ⁶
Author Information

1. Department of Hematology, The Central Hospital of Xuzhou, Xuzhou 221009, Jiangsu Province, China.
2. Laboratory of Hematology, Third Hospital Affiliated to Suzhou University, The First People's Hospital of Changzhou, Changzhou 213003, Jiangsu Province, China.
3. Department of Hematology, Third Hospital Affiliated to Suzhou University, The First People's Hospital of Changzhou, Changzhou 213003, Jiangsu Province, China.
4. Jiangsu Institute of Hematology, The First Hospital Affiliated to Suzhou University, Suzhou 215006, Jiangsu Province, China.
5. Department of Hematology, Children's Hospital of Suzhou University, Suzhou 215006, Jiangsu Province, China.
6. Department of Hematology, Third Hospital Affiliated to Suzhou University, The First People's Hospital of Changzhou, Changzhou 213003, Jiangsu Province, China. E-mail: guweiying2001@163.com.
Publication Type:Journal Article
From: Journal of Experimental Hematology 2017;25(1):61-65
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo investigate the percentage of blasts with the CD34/CD38/CD123phenotype in de novo acute myeloid leukemia (AML) patients and analyse its correlation with prognosis.
METHODSThe percentage of CD34/CD38/CD123cells in the blast population of 148 newly diagnosed patients with AML was determined by using flow cytometry and its correlation with complete response, disease-free survival and overall survival were evaluated.
RESULTSThe median percentage of CD34/CD38/CD123cells in newly diagnosed patients was 2.8% (ranged from 0.01 to 67%). The high expression of CD34/CD38/CD123in AML patients positively correlated with the NPM1 wild-type (χ=5.194,P<0.05), but did not relate with the positive FLT3-ITD mutations (χ=0.418,P>0.05). Further multivariable analysis showed that the higher expression of the CD34/CD38/CD123was associated with lower complete remission (P<0.05), worse disease-free survival(P<0.01) and shorter overall survival(P<0.01) in AML patients.
CONCLUSIONThe percentage of CD34/CD38/CD123cells at diagnosis significantly correlates with the response to treatment and survival. This prognostic marker may be used to rapidly identify the risk of treatment failure in clinical practice.